{"doi":"10.3390/nu14132683","title":"Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study","abstract":"<jats:p>The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels &lt; 50 nmol/L). In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively. Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort). The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients. In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control. Cholecalciferol treatment increased 25OHD levels and reduced parathormone, total cholesterol, and low-density lipoprotein cholesterol levels in C-cohort patients, whereas no significant changes in these parameters were observed in P-cohort patients. The miR-21 circulating levels did not change in the C- or the P-cohort patients upon treatment. Calcitriol treatment did not affect miR-21 levels in HEK-293 cells. In conclusion, hypovitaminosis D correction ameliorated the cardiovascular risk profiles in hypertensive patients treated with cholecalciferol but did not influence the miR-21 expression.</jats:p>","journal":"Nutrients","year":2022,"id":638092,"datarank":0.40620753016533157,"base_score":2.70805020110221,"endowment":2.70805020110221,"self_citation_contribution":0.40620753016533157,"citation_network_contribution":0.0,"self_endowment_contribution":0.40620753016533157,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":14,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1657110,"name":"Lanfranco D′Elia","orcid":"0000-0002-1782-0211","position":1,"is_corresponding":false},{"id":1657113,"name":"Veronica Abate","orcid":"0000-0003-0085-0067","position":2,"is_corresponding":false},{"id":1657114,"name":"Andrea Rebellato","orcid":null,"position":3,"is_corresponding":false},{"id":1657115,"name":"Ilaria Buondonno","orcid":null,"position":4,"is_corresponding":false},{"id":790685,"name":"Mariangela Succoio","orcid":"0000-0001-9939-1619","position":5,"is_corresponding":false},{"id":653563,"name":"Fabio Martinelli","orcid":"0000-0002-4863-1747","position":6,"is_corresponding":false},{"id":1657116,"name":"Riccardo Muscariello","orcid":null,"position":7,"is_corresponding":false},{"id":1657117,"name":"Gianpaolo De Filippo","orcid":"0000-0003-1313-5599","position":8,"is_corresponding":false},{"id":1657118,"name":"Patrizia D′Amelio","orcid":"0000-0002-4467-8337","position":9,"is_corresponding":false},{"id":1657119,"name":"Francesco Fallo","orcid":"0000-0002-7511-0226","position":10,"is_corresponding":false},{"id":1657120,"name":"Pasquale Strazzullo","orcid":null,"position":11,"is_corresponding":false},{"id":1657121,"name":"Raffaella Faraonio","orcid":"0000-0002-6563-8158","position":12,"is_corresponding":false},{"id":1657107,"name":"Domenico Rendina","orcid":"0000-0002-0331-0392","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study","abstract":"<jats:p>The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels &lt; 50 nmol/L). In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively. Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort). The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients. In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control. Cholecalciferol treatment increased 25OHD levels and reduced parathormone, total cholesterol, and low-density lipoprotein cholesterol levels in C-cohort patients, whereas no significant changes in these parameters were observed in P-cohort patients. The miR-21 circulating levels did not change in the C- or the P-cohort patients upon treatment. Calcitriol treatment did not affect miR-21 levels in HEK-293 cells. In conclusion, hypovitaminosis D correction ameliorated the cardiovascular risk profiles in hypertensive patients treated with cholecalciferol but did not influence the miR-21 expression.</jats:p>","is_dataset_classified":null,"base_score":2.70805020110221,"endowment":2.70805020110221,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35807864","pmcid":"PMC9268320","openalex_id":"https://openalex.org/W4284991349","authors":[],"funders":[{"funder_name":"SIIA research","grant_id":"2011","title":null},{"funder_name":"SIIA research","grant_id":"2014","title":null}],"total_grants":2,"fwci":1.4987,"citation_percentile":0.82173537,"influential_citations":0,"citation_trend":[{"year":2022,"count":2},{"year":2023,"count":3},{"year":2024,"count":3},{"year":2025,"count":3},{"year":2026,"count":3}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2072-6643/14/13/2683/pdf?version=1656417433","host_type":"journal"},{"url":"https://www.mdpi.com/2072-6643/14/13/2683/pdf?version=1656417433","host_type":"publisher"},{"url":"https://www.mdpi.com/2072-6643/14/13/2683/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/nu14132683","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/35807864","host_type":"repository"},{"url":"https://iris.unil.ch/handle/iris/154773","host_type":"repository"},{"url":"https://doaj.org/article/9a6700d35ff64f8988021ea9c5eeb95e","host_type":"repository"},{"url":"https://dx.doi.org/10.3390/nu14132683","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9268320","host_type":"repository"},{"url":"https://serval.unil.ch/notice/serval:BIB_D9D07784DA58","host_type":"repository"},{"url":"https://iris.unil.ch/bitstreams/df913c50-4e2f-4c35-abb0-a719056c5acd/download","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC9268320","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9268320?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Vitamin D Research Studies","Adipokines, Inflammation, and Metabolic Diseases","Cardiovascular Disease and Adiposity","Calcitriol","Cardiovascular Diseases","Cholecalciferol","Cholesterol","Dietary Supplements","Double-Blind Method","HEK293 Cells","Heart Disease Risk Factors","Humans","Hypertension","MicroRNAs","Risk Factors","Vitamin D","Vitamin D Deficiency","Vitamins"],"mesh_terms":["Heart Disease Risk Factors","Calcitriol","Cardiovascular Diseases","Cholecalciferol","Cholesterol","Double-Blind Method","Humans","Hypertension","Risk Factors","Vitamin D","Vitamin D Deficiency","Vitamins","Dietary Supplements","MicroRNAs","HEK293 Cells"],"keywords":["Cholecalciferol","Medicine","Vitamin D and neurology","Calcitriol","Internal medicine","Cohort","Endocrinology","Placebo","Gastroenterology","Pathology","Hypertension","Inflammation","Clinical Trial","Hypovitaminosis D","Mir-21"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"eudract"},{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T20:05:49.949851Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}